Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices 14535 

The Board is designed to provide 

guidance on extramural scientific 

program matters, including the: (1) 

Review of extramural research concepts 

for funding opportunity 

announcements; (2) conduct of 

Secondary Peer Review of extramural 

research grants, cooperative agreements, 

and contracts applications received in 

response to the funding opportunity 

announcements as it relates to the 

Center’s programmatic balance and 

mission; (3) submission of secondary 

review recommendations to the Center 

Director of applications to be considered 

for funding support; (4) review of 

research portfolios, and (5) review of 

program proposals. 

Matters To Be Considered: The agenda 

will include an update on the Traumatic 

Brain Injury (TBI) Research Priorities; 

Older Adult Falls Research Priorities; 

the Diversity, Equity, Belonging, 

Inclusion and Accessibility (DEBIA) 

Strategic Plan; and Health Equity. 

Agenda items are subject to change as 

priorities dictate. 

Public Participation 

Written Public Comment: Written 

comments must be received on or before 

5:00 p.m., EDT, April 18, 2022, by email 

at ncipcbsc@cdc.gov. All written 

comments will be included as part of 

the meeting minutes. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. 

Individuals wishing to pre-register for 

public comment must do so by 

Wednesday, April 6, 2022, at 5:00 p.m., 

EDT. Those pre-registering for public 

comment must also register for the 

meeting using the link below. 

Oral Public Comment Procedure: 

Individuals registered to provide public 

comment will be called upon first to 

speak based on the order of registration, 

followed by others from the public. All 

public comments will be limited to two 

(2) minutes per speaker. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05429 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–007, COVID–19 and Women: An 

Assessment of Challenges and Lessons 

Learned to Enhance Public Health 

Emergency Preparedness for Women 

and Families. 

Date: May 11, 2022 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, Email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05431 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). This 

meeting is open to the public, limited 

only by the webcast lines available. 

Check the CLIAC website on the day of 

the meeting for the web conference link 

https://www.cdc.gov/cliac. Time will be 

available for public comment. 

DATES: The meeting will be held on 

April 13, 2022, from 11:00 a.m. to 6:00 

p.m., EDT, and April 14, 2022, from 

11:00 a.m. to 6:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials including instructions for 

accessing the live meeting broadcast 

will be available on the CLIAC website 

at https://www.cdc.gov/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Senior Advisor for Clinical Laboratories, 

Division of Laboratory Systems, Center 

for Surveillance, Epidemiology and 

Laboratory Services, Office of Public 

Health Scientific Services, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop V24–3, 

Atlanta, Georgia 30329–4018, 

Telephone: (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: This Committee is charged 

with providing scientific and technical 

advice and guidance to the Secretary, 

HHS; the Assistant Secretary for Health; 

the Director, CDC; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) standards. Examples include 

providing guidance on studies designed 

to improve safety, effectiveness, 

efficiency, timeliness, equity, and 


khammond on DSKJM1Z7X2PROD with NOTICES
14536 Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices 

patient-centeredness of laboratory 

services; revisions to the standards 

under which clinical laboratories are 

regulated; the impact of proposed 

revisions to the standards on medical 

and laboratory practice; and the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, the 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters To Be Considered: The agenda 

will include agency updates from CDC, 

CMS, and FDA. In addition to the 

general updates, an update will be 

provided on the ongoing CLIAC 

workgroups. Presentations and CLIAC 

discussion will focus on the future of 

laboratory medicine, especially testing 

in non-traditional sites. There will be an 

extended public comment session 

focusing on anticipated changes in 

testing practices, personnel issues, and 

emerging technologies used in nontraditional testing sites. Agenda items 

are subject to change as priorities 

dictate. 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person at least five business days prior 

to the meeting date. For individuals or 

groups unable to attend the meeting, 

CLIAC accepts written comments until 

the date of the meeting (unless 

otherwise stated). However, it is 

requested that comments be submitted 

at least five business days prior to the 

meeting date so that the comments may 

be made available to the Committee for 

their consideration and public 

distribution. All written comments will 

be included in the meeting Summary 

Report posted on the CLIAC website. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05430 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10573 and CMS– 

10106] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

May 16, 2022. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: llll, Room C4– 

26–05, 7500 Security Boulevard, 

Baltimore, Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

https://www.cms.gov/Regulations-andGuidance/Legislation/Paperwork

ReductionActof1995/PRA-Listing. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10573 Reform of Requirements 

for Long-Term Care Facilities 

CMS–10106 Medicare Authorization 

to Disclose Personal Health 

Information 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Reform of 

Requirements for Long-Term Care 

Facilities; Use: According to our data, as 

of April 2, 2021, there were 15,372 LTC 


khammond on DSKJM1Z7X2PROD with NOTICES